April 5, 2022
C-Path Receives Qualification Opinion from EMA on Type 1 Diabetes Biomarker Initiative: C-Path’s Type 1 Diabetes Consortium (T1DC) announced that the European Medicines Agency (EMA) has issued a positive qualification opinion for pancreatic islet autoantibodies as enrichment biomarkers for type 1 diabetes (T1D) prevention trials.
